Pfizer vaccine for children below 12: Pfizer announced on Tuesday, June 9 that it will start testing its COVID-19 vaccine, made in collaboration with BioNTech SA in a larger group of children under the age of 12. The vaccine has already been authorised for use in children above the age of 12.
The testing will be done in children of age 5 to 12, and 6 months to 5 years separately. Lower doses of the vaccine shot for the respective age groups have already been shortlisted on basis of results from the early stage of the trial. The vaccine is already authorised in Europe, Canada and the United States for inoculation of children above the age 12.
In the study of children under 12 years of age, a total of 4,500 participants will be enrolled from more than 80 clinical sites in Finland, Poland, Spain and the United States.
On the basis of results of tolerability, safety and immune response generated by about 144 children in Phase 1, the company said that it will inoculate participating children between 5 to 12 years of age with a dose of 10 micrograms, and a dose of three micrograms in children of six months to five years. The approved dosage of the vaccine for adults is 30 micrograms.
According to a spokesperson at Pfizer, the company expects data of tests in five to 11 years olds by September and will seek approval for emergency use of the vaccine in the said age group later the same month. The test data of two to five-year-olds is expected to arrive soon after that. However, test results for children between six months to two years of age are expected to be available only in October or November 2021.
Scientists across the world are studying the possibility of a link between mRNA vaccines and heart inflammation in young men. COVID-19 vaccines rolled out by both Pfizer and Moderna are mRNA based vaccines, and are suspected to cause myocarditis. A small number of mild myocarditis cases were found in Israel after receiving Pfizer vaccines, said the Health Ministry of Israel.
Picture Credit: Business Standard